At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRVO CervoMed
Not Yet Opened 03-09 16:00:00 EDT
4.54
+0.43
+10.46%
盘后4.75
+0.21+4.63%
19:07 EDT
High4.95Low4.10Vol316.38K
Open4.11D1 Closing4.11Amplitude20.68%
Mkt Cap42.01MTradable Cap22.40MTotal Shares9.25M
T/O1.47MT/O Rate6.41%Tradable Shares4.93M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

CervoMed to Participate in Leerink Global Healthcare Conference and 38th Annual ROTH Conference
Reuters  ·  03-05
CervoMed to Participate in Leerink Global Healthcare Conference and 38th Annual ROTH Conference
CervoMed to Participate in Upcoming Investor Conferences
GlobeNewswire  ·  03-05
CervoMed to Participate in Upcoming Investor Conferences
CervoMed Advances Neflamapimod With Phase 1 Completion
TIPRANKS  ·  03-05
CervoMed Advances Neflamapimod With Phase 1 Completion
CervoMed Is Maintained at Buy by D. Boral Capital
Dow Jones  ·  03-05
CervoMed Is Maintained at Buy by D. Boral Capital
CervoMed Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders
Reuters  ·  03-04
CervoMed Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders
BRIEF-Cervomed Announces Selection Of Formulation And Dosing Regimen For Planned Phase 3 Trial In Patients With Dementia With Lewy Bodies
Reuters  ·  03-04
BRIEF-Cervomed Announces Selection Of Formulation And Dosing Regimen For Planned Phase 3 Trial In Patients With Dementia With Lewy Bodies
CervoMed selects 50mg TID neflamapimod dosing for planned Phase 3 DLB trial
Reuters  ·  03-04
CervoMed selects 50mg TID neflamapimod dosing for planned Phase 3 DLB trial
CervoMed Inc - to Initiate Global Phase 3 Trial in Dlb in Second Half of 2026
THOMSON REUTERS  ·  03-04
CervoMed Inc - to Initiate Global Phase 3 Trial in Dlb in Second Half of 2026
CervoMed: Capital-Efficient Expansion of Neflamapimod Into ALS Platform Trial Supports Buy Rating and $20 Target
TIPRANKS  ·  02-19
CervoMed: Capital-Efficient Expansion of Neflamapimod Into ALS Platform Trial Supports Buy Rating and $20 Target
CervoMed Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders
Reuters  ·  02-18
CervoMed Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders
CervoMed Is Maintained at Buy by D. Boral Capital
Dow Jones  ·  02-18
CervoMed Is Maintained at Buy by D. Boral Capital
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform
TIPRANKS  ·  02-18
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform
BRIEF-Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform
Reuters  ·  02-18
BRIEF-Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform
CervoMed: Maintain Focus on Dlb, Take Steps to Initiate Planned Phase 3 Trial Later This Year
THOMSON REUTERS  ·  02-18
CervoMed: Maintain Focus on Dlb, Take Steps to Initiate Planned Phase 3 Trial Later This Year
CervoMed’s Neflamapimod Elected for Inclusion in UK Experts-ALS Platform Designed to Prioritize Promising Treatments for Amyotrophic Lateral Sclerosis
THOMSON REUTERS  ·  02-18
CervoMed’s Neflamapimod Elected for Inclusion in UK Experts-ALS Platform Designed to Prioritize Promising Treatments for Amyotrophic Lateral Sclerosis
CervoMed Inc - First ALS Patient Expected to Be Dosed by End of 2026
THOMSON REUTERS  ·  02-18
CervoMed Inc - First ALS Patient Expected to Be Dosed by End of 2026
CervoMed Joins UK EXPERTS-ALS Trial Platform to Test Neflamapimod in ALS
Reuters  ·  02-18
CervoMed Joins UK EXPERTS-ALS Trial Platform to Test Neflamapimod in ALS
CervoMed (NASDAQ:CRVO) Will Have To Spend Its Cash Wisely
Simply Wall St.  ·  02-18
CervoMed (NASDAQ:CRVO) Will Have To Spend Its Cash Wisely
Alpha Buying: Managing Biotech Risk With Insider Clues
Benzinga_recent_news  ·  01-16
Alpha Buying: Managing Biotech Risk With Insider Clues
CervoMed Releases Updated Investor Presentation and Business Overview
TIPRANKS  ·  01-09
CervoMed Releases Updated Investor Presentation and Business Overview

Introduction

Company Name.
CervoMed
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Issue price:
--